MED21

Across TCGA pan-cancer cohorts, MED21 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MED21 data layer compared with 21 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MED21 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MED21 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

PDAC, UCEC, and HNSC are the cancer types where MED21 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.173	0.502	.011	12	view →
UCEC	DFS	Tertile	II,III,IV	1.000	0.555	.020	8	view →
HNSC	OS	Quartile	All	0.763	0.941	.023	7	view →
LUAD	OS	Quartile	All	0.903	0.680	.023	4	view →
CCRCC	DFS	Quartile	II,III,IV	0.835	1.000	.030	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MED21–PDAC (DFS)

Open the PDAC breakdown →